{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:49:18Z","timestamp":1792594158709,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.survophthal.2015.12.007","type":"journal-article","created":{"date-parts":[[2015,12,19]],"date-time":"2015-12-19T10:07:41Z","timestamp":1450519661000},"page":"314-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Update on ocular cicatricial pemphigoid and emerging treatments"],"prefix":"10.1016","volume":"61","author":[{"given":"Munther M.","family":"Queisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Zein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9898-7354","authenticated-orcid":false,"given":"Neerav","family":"Lamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halea","family":"Meese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles Stephen","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.survophthal.2015.12.007_bib1","first-page":"273","article-title":"Cyclophosphamide therapy of Behcet's disease","volume":"43","author":"Buckley","year":"1969","journal-title":"J\u00a0Allergy"},{"issue":"11","key":"10.1016\/j.survophthal.2015.12.007_bib2","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/archderm.142.11.1457","article-title":"Successful treatment of mucous membrane pemphigoid with etanercept in 3 patients","volume":"142","author":"Canizares","year":"2006","journal-title":"Arch Dermatol"},{"issue":"9","key":"10.1016\/j.survophthal.2015.12.007_bib3","first-page":"501","article-title":"[Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid]","volume":"77","author":"Celis S\u00e1nchez","year":"2002","journal-title":"Arch Soc Esp Oftalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2015.12.007_bib4","first-page":"2283","article-title":"The role of antibody to human beta4 integrin in conjunctival basement membrane separation: possible in\u00a0vitro model for ocular cicatricial pemphigoid","volume":"40","author":"Chan","year":"1999","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.survophthal.2015.12.007_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajo.2009.09.026","article-title":"Mycophenolate mofetil for ocular inflammation","volume":"149","author":"Daniel","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.survophthal.2015.12.007_bib6","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0161-6420(01)00657-1","article-title":"Treatment of ocular cicatricial pemphigoid with sulfasalazine","volume":"108","author":"Doan","year":"2001","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.survophthal.2015.12.007_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0161-6420(99)90022-2","article-title":"Subconjunctival mitomycin C for the treatment of ocular cicatricial pemphigoid","volume":"106","author":"Donnenfeld","year":"1999","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2015.12.007_bib8","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3109\/09273948.2011.624288","article-title":"Long-term results of therapy with mycophenolate mofetil in ocular mucous membrane pemphigoid","volume":"19","author":"Doycheva","year":"2011","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.survophthal.2015.12.007_bib9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.ophtha.2003.08.034","article-title":"Pulse IV cyclophosphamide in ocular inflammatory disease: efficacy and short-term safety","volume":"111","author":"Durrani","year":"2004","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.survophthal.2015.12.007_bib10","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.survophthal.2011.05.003","article-title":"Systemic therapy with conventional and novel immunomodulatory agents for ocular inflammatory disease","volume":"56","author":"Durrani","year":"2011","journal-title":"Surv Ophthalmol"},{"issue":"5","key":"10.1016\/j.survophthal.2015.12.007_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.5301\/EJO.2011.6294","article-title":"Pentoxifylline (anti-tumor necrosis factor drug): effective adjuvant therapy in the control of ocular cicatricial pemphigoid","volume":"21","author":"El Darouti","year":"2011","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2015.12.007_bib12","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/art.1780110205","article-title":"Long-term cyclophosphamide therapy in rheumatoid arthritis","volume":"11","author":"Fosdick","year":"1968","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.survophthal.2015.12.007_bib13","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"5","key":"10.1016\/j.survophthal.2015.12.007_bib14","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2015.12.007_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0161-6420(82)34791-0","article-title":"Immunosuppressive therapy for progressive ocular cicatricial pemphigoid","volume":"89","author":"Foster","year":"1982","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.survophthal.2015.12.007_bib16","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/archderm.139.8.1083","article-title":"Ocular mucous membrane pemphigoid and ocular pemphigus vulgaris treated topically with tacrolimus ointment","volume":"139","author":"Hall","year":"2003","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.survophthal.2015.12.007_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00003226-199309000-00008","article-title":"Topical cyclosporin A in the treatment of anterior segment inflammatory disease","volume":"12","author":"Holland","year":"1993","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.survophthal.2015.12.007_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.survophthal.2015.12.007_bib19","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.survophthal.2015.12.007_bib20","first-page":"379","article-title":"Identification of ocular cicatricial pemphigoid antibody binding site(s) in human beta4 integrin","volume":"42","author":"Kumari","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2015.12.007_bib21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1076\/0271-3683(200008)2121-VFT646","article-title":"Influence of intravenous immunoglobulin therapy on serum levels of anti-beta 4 antibodies in ocular cicatricial pemphigoid. A correlation with disease activity. A preliminary study","volume":"21","author":"Letko","year":"2000","journal-title":"Curr Eye Res"},{"issue":"4","key":"10.1016\/j.survophthal.2015.12.007_bib22","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ophtha.2003.07.010","article-title":"Methotrexate therapy for ocular cicatricial pemphigoid","volume":"111","author":"McCluskey","year":"2004","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.survophthal.2015.12.007_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0151-9638(06)70869-9","article-title":"[Topical tacrolimus treatment for ocular cicatricial pemphigoid]","volume":"133","author":"Michel","year":"2006","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.survophthal.2015.12.007_bib24","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0161-6420(01)00863-6","article-title":"The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.survophthal.2015.12.007_bib25","doi-asserted-by":"crossref","first-page":"7707","DOI":"10.1167\/iovs.12-11404","article-title":"Identification of epitopes within integrin \u03b24 for binding of auto-antibodies in ocular cicatricial and mucous membrane pemphigoid: preliminary report","volume":"54","author":"Rashid","year":"2013","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"10.1016\/j.survophthal.2015.12.007_bib26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2008.10.061","article-title":"Transition from pemphigus foliaceus to bullous pemphigoid: intermolecular B-cell epitope spreading without IgG subclass shifting","volume":"61","author":"Recke","year":"2009","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.survophthal.2015.12.007_bib27","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.ophtha.2003.11.012","article-title":"Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up","volume":"111","author":"Sami","year":"2004","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.survophthal.2015.12.007_bib28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S0002-9394(14)70495-7","article-title":"Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices","volume":"122","author":"Secchi","year":"1996","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2015.12.007_bib29","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jtos.2013.02.003","article-title":"Current medical treatment of ocular mucous membrane pemphigoid","volume":"11","author":"Sobolewska","year":"2013","journal-title":"Ocul Surf"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625715002271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625715002271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T11:41:18Z","timestamp":1758541278000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625715002271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0039625715002271"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2015.12.007","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on ocular cicatricial pemphigoid and emerging treatments","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2015.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}